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The use of serological tests for syphilis plays an important role in the management of disease transmission. Screening tests for syphilis have been available since the early 1900s. The increase in the number of cases over the past few years has focused attention on the development of new and improved methods such as the enzyme immunoassay for detecting antibodies to Treponema pallidum. This method was first described in 1975 by Veldkamp and Visser, who concluded that it might be used in the future as a screening test (29) . Since that time, various versions of the assay have been evaluated in Europe and the United States, and opinions about its use as a screening tool have varied (4, 7, 8, 16, 21, 23, 32) . Because The six false-positive RPR results focus our attention on a problem with the RPR screen. The specificity of cardiolipin assays has been shown to be lower than the specificity of treponemal assays (13) . Biological false positives in cardiolipin tests are believed to occur in 1 to 2% of the general population (14) . Some reports have shown higher rates (22) , but the rate depends on the population studied. If the population includes patients with other treponemal diseases (3), autoimmune disorders such as systemic lupus erythematosus (5, 17, 25) , drug addiction (12, 20, 25) , genital herpes (20, 30) , or leprosy (20, 25) , or if there are elderly (9, 20, 25) Because the sample was initially run adjacent to a positive sample in the CAPTIA Syphilis-G assay and the possibility of carryover could not be disproved, the results for this sample were considered incomplete and the patient's diagnosis was considered inconclusive. Of the 11 remaining samples that were nonreactive in the RPR test and whose results were unconfirmed by standard treponemal antibody tests, 10 were diluted and found to have no RPR prozone reactivity. The other sample was of insufficient quantity to be tested for the prozone effect.
The prozone phenomenon occurs in particle agglutination as a consequence of an imbalance between antigen and antibody concentrations. Incomplete cross-linking of particles yields false-negative results. Although our population of patient samples did not reveal any patients with prozone, it is well known that up to 2% of the sera from patients with secondary syphilis yield false-negative RPR results due to the prozone phenomenon (14) . Because treponemal antibody tests are not subject to this phenomenon, the treponemal enzyme immunoassay could be more helpful in such situations by providing a positive result (32) . The Of the 1,000 study samples, 50 yielded positive or equivocal results when screened by the CAPTIA Syphilis-G assay. Two of these samples were from patients with inconclusive diagnoses as described above. The results for 35 samples were confirmed by reactive FTA-ABS and/or MHA-TP results. The results for the remaining 13 samples (7 positive and 6 equivocal) were not confirmed by the standard treponemal tests. Upon repeat testing in the CAPTIA Syphilis-G assay, these 13 samples with unconfirmed results were determined to be negative. We are currently investigating the possibility that the instrument used in diluting these 13 samples was subject to sampling error or carryover. Until the source of this problem can be identified, repeat testing of all positive samples is necessary.
We also recommend testing positive and equivocal CAPTIA Syphilis-G samples with the RPR titer test or another cardiolipin test. Because treponemal antibodies usually remain reactive for life, completing the serology profile with the RPR titer is helpful in determining the stage of disease and monitoring the disease. For example, the presence of treponemal antibodies in the absence of cardiolipin antibodies could indicate latent syphilis. Levels of cardiolipin antibodies decline during latent syphilis, and samples from 20 to 25% of patients become nonreactive in cardiolipin tests (3, 9, 15) . The presence of treponemal antibodies in the absence of cardiolipin antibodies may also indicate primary syphilis (1, 6, 9, 11, 20) . The ability of the IgG enzyme immunoassay to detect treponemal antibodies in primary syphilis sooner than cardiolipin tests has also been documented (21, 32) . Our suggested testing protocol of follow-up testing with the RPR test would provide important information to physicians for diagnosis and treatment as well as to health departments for purposes of contact tracing.
Of the 1,000 study samples, 1 sample yielded a negative CAPTIA Syphilis-G result but was reactive once and nonreactive once in the MHA-TP test when this test was performed twice. As described above, this patient's diagnosis was considered inconclusive. Two study samples produced negative results in the CAPTIA Syphilis-G assay and were reactive in the RPR and FTA-ABS tests. These two samples were assayed again in the CAPTIA Syphilis-G test. One result changed from an index of 0.8 to an index of 0.9-equivocal, suggesting a difference due to interrun variation. The second result changed from an index of 0.3 to an index of 1.3-positive. The difference observed in this result may have been a consequence of an instrument-related error in sampling or an inadequately coated microwell. The index of 1.3 was considered more reliable since it was confirmed by the standard treponemal antibody tests.
Displayed in Table 2 is a summary of the diagnoses and screen results for the 1,000 study samples. After discrepancies due to technical problems were reconciled, fewer false positives and false negatives were found in the CAPTIA Syphilis-G assay.
Although current standard treponemal antibody tests are considered very sensitive and very specific, historically they The treponemal enzyme immunoassay could achieve these same goals. First, the sensitivities and specificities of the CAPTIA Syphilis-G and RPR assays in detecting untreated cases of syphilis were calculated. Samples from 3 treated patients yielded negative RPR results and positive or equivocal CAPTIA Syphilis-G results. These contradictory results are understandable and were therefore omitted from the calculations. Table 3 indicates that the CAPTIA Syphilis-G test is more sensitive than the RPR test in detecting untreated cases of syphilis. Our results support the conclusions from other studies in which the CAPTIA Syphilis-G assay was found to be very sensitive and specific for treponemal antibodies (16, 31) .
Second, the potential for automation makes the treponemal antibody enzyme immunoassay a more objective test and provides rapid results for batch testing in high-volume laboratories. While our laboratory could experience a cost benefit due to a high volume of samples with a relatively low positivity rate, clinics and large hospital laboratories in which a higher positivity rate exists may not experience such a benefit. How- Finally, because of its sensitivity and specificity, using the assay as a screening test in the field would also provide many benefits. Many enzyme immunoassays have been modified to rapid-membrane formats that require little or no instrumentation. This modification would be very useful for field testing. A recent study involved initiating a program of screening drug users in high-risk areas such as crack houses and drug sale areas (19) . This program was successful in detecting new cases, but some patients could not be located for follow-up examination and treatment despite the short period between the time of phlebotomy and the time at which results were obtained. The study demonstrated that the best approach would be to perform a test on-site and obtain a result immediately. Therefore, a quick, portable treponemal screening test would be very beneficial. The membrane format of testing has already been adopted in many areas of infectious disease serology. We believe that it is realistic to predict that such a method will soon be developed for syphilis serology as well. A review of our study's results and other potential benefits leads us to consider the CAPTIA Syphilis-G enzyme immunoassay for use as a possible alternate screening test, should the test achieve standard status by the Centers for Disease Control and Prevention. With promising new syphilis tests being developed, we find that it is time for laboratories in the United States to consider improving screening tests and testing protocols. With numbers of syphilis cases remaining higher than our national goal, laboratories need to provide the best screening tests possible to help curb the spread of this infectious disease.
